OncologyTube Professional - Patients Click Here
262,292 video views
Loading........
Description: Despite major advancements in the understanding of the genetic drivers of acute myeloid leukemia (AML) and the pathophysiology of the disease, standard treatment options for AML patients have not expe...
02:29
Despite major advancements in the understanding of the genetic drivers of acute myeloid leukemia (AML) and the pathophysiology of the disease, standard treatment options for AML patients have not experienced any major changes in the past few decades. Clinicians are often hesitant to send patients into clinical trials if the condition of the patient...
by:VJOncology | 5 views
01:31
Despite recent approvals of drugs targeting acute myeloid leukemia (AML), overall survival and complete remission rates remain suboptimal. In this interview, Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, explains how he encourages his AML patients to participate in clinical trials, especially those who are in a rel...
by:VJOncology | 5 views
02:00
Gail Roboz, MD, from the Weill Medical College of Cornell University, New York City, NY, explores exciting next-generation agents for the treatment of acute myeloid leukemia (AML), such as guadecitabine, a next-generation DNA hypomethylating agent that has the potential to be more effective than dec...
by:VJOncology | 4 views
01:47
Treatment outcomes for acute myeloid leukemia (AML) patients treated with immunotherapy have significantly lagged behind those achieved for acute lymphoblastic leukemia (ALL), and this is due to the fact that eliminating the B-cell lineage for the management of ALL is less problematic than eliminati...
by:VJOncology | 10 views
02:37
Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the mechanisms of resistance to targeted therapies such as enasidenib and ivosidenib in acute myeloid leukemia (AML). Primary resistance, defined by a complete lack of response to the drug, is mediated by co-occurring mutations and is most common in patients w...
by:VJOncology | 5 views
02:37
Patients suffering from acute myeloid leukemia (AML) who have achieved complete remission are still at risk of relapse. Assessing blood counts or examining the morphology of the bone marrow is not sufficient to determine the levels of residual leukemic cells remaining upon completion of therapy. Here, Gail Roboz, MD, from Weill Medical College of C...
by:VJOncology | 9 views
01:37
Traditionally, the standard therapy for the management of acute myeloid leukemia (AML) in elderly patients has been low-dose cytarabine, but hypomethylating agents (HMAs) have quickly become the backbone of AML treatment in many countries. Here, Chrisoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, provides evidence...
by:VJOncology | 5 views
01:23
The side effects of isocitrate dehydrogenase (IDH) inhibitors for the treatment of acute myeloid leukemia (AML) include gastrointestina​l toxicity, leukocytosis, differentiation syndrome and QT prolongation, among many others. Here, Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, Ne...
by:VJOncology | 5 views
01:55
Gemtuzumab ozogamicin is a monoclonal antibody drug for the treatment of acute myeloid leukemia (AML). This drug uses a different strategy to classical chemotherapeuti​c agents, and the development of other similar drugs is expected to drastically improve the outcomes of patients with AML. In this interview, Chrisoph Röllig, MD, from the University ...
by:VJOncology | 5 views
02:19
The average age of people suffering from acute myeloid leukemia (AML) is around 60 to 70 years, and there are many issues surrounding the use of chemotherapy drugs in this population. In this interview, Gail Roboz, MD, from Weill Medical College of Cornell University, New York City, NY, highlights t...
by:VJOncology | 6 views

About VJOncology
Description: The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of solid tumors. Our goal is to expedite learning through the sharing of new data and expert opinion, and to rapidly disseminate the latest news and information to healthcare professionals, worldwide, on a range of innovative digital media – including video and blog formats. VJOncology content will be led by an editorial board of highly respected thought leaders with a combined expertise that spans the spectrum of solid tumors. All content will be created and published under the guidance of this board of world-leading experts.

Links
Channel Url: